Do analysts prefer VERO or VRAX?

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 1,236.90%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, VERO or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Venus Concept. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Venus Concept $58.88M 0.01 -$47M -$48.84 N/A Virax Biolabs Group $12.42K 119.97 -$5.02M N/A N/A

Do analysts prefer VERO or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer VERO or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, VERO or PFSA?

Profusa has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Venus Concept $58.88M 0.01 -$47M -$48.84 N/A Profusa $100K 8.66 -$35.82M -$5.62 thousand N/A

Is VERO or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Profusa N/A N/A -1,731.09%

Do analysts prefer VERO or BTCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERO or BTCY more profitable?

Biotricity has a net margin of -80.42% compared to Venus Concept's net margin of -92.76%. Biotricity's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Biotricity -80.42% N/A -188.47%

Do analysts recommend GCTK or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GCTK or VERO more profitable?

GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Venus Concept's return on equity of -1,904.25% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% Venus Concept -92.76% -1,904.25% -85.22%

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 10/9/2026

Compare

VERO vs. VRAX, BBLG, PFSA, BTCY, and GCTK

Should you buy Venus Concept stock or one of its competitors? Venus Concept's main competitors and comparable companies include Virax Biolabs Group (VRAX), Bone Biologics (BBLG), Profusa (PFSA), Biotricity (BTCY), and GlucoTrack (GCTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Venus Concept compare to Virax Biolabs Group?

Venus Concept (NASDAQ:VERO) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 1,236.90%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Virax Biolabs Group's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has lower revenue, but higher earnings than Venus Concept.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Virax Biolabs Group	$12.42K	119.97	-$5.02M	N/A	N/A

In the previous week, Virax Biolabs Group had 3 more articles in the media than Venus Concept. MarketBeat recorded 3 mentions for Virax Biolabs Group and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Virax Biolabs Group	Neutral

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Virax Biolabs Group beats Venus Concept on 11 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Bone Biologics?

Venus Concept (NASDAQ:VERO) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Bone Biologics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bone Biologics' return on equity of -57.87% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Bone Biologics	N/A	-57.87%	-53.65%

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 5.0% of Bone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Bone Biologics has lower revenue, but higher earnings than Venus Concept. Bone Biologics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

In the previous week, Bone Biologics had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Bone Biologics and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Bone Biologics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bone Biologics beats Venus Concept on 7 of the 11 factors compared between the two stocks.

How does Venus Concept compare to Profusa?

Venus Concept (NASDAQ:VERO) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Profusa has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 15.0% of Profusa shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Profusa had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for Profusa and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Profusa'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Profusa	Neutral

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Profusa	N/A	N/A	-1,731.09%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Profusa	$100K	8.66	-$35.82M	-$5.62 thousand	N/A

Summary

Profusa beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Biotricity?

Venus Concept (NASDAQ:VERO) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Biotricity has lower revenue, but higher earnings than Venus Concept. Biotricity is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Biotricity	$12.06M	0.09	-$14.09M	-$0.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Biotricity	Neutral

Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Biotricity has a net margin of -80.42% compared to Venus Concept's net margin of -92.76%. Biotricity's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Biotricity	-80.42%	N/A	-188.47%

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 1.6% of Biotricity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Venus Concept and Biotricity tied by winning 6 of the 12 factors compared between the two stocks.

How does Venus Concept compare to GlucoTrack?

GlucoTrack (NASDAQ:GCTK) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 5.9% of GlucoTrack shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GlucoTrack had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for GlucoTrack and 0 mentions for Venus Concept. GlucoTrack's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
GlucoTrack	Neutral
Venus Concept	Neutral

GlucoTrack has higher earnings, but lower revenue than Venus Concept. GlucoTrack is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Venus Concept's return on equity of -1,904.25% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

Venus Concept beats GlucoTrack on 7 of the 11 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$442K	$5.44B	$7.17B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-0.01	25.57	274.15	26.16
Price / Sales	0.01	83.34	635.99	107.44
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	0.07	5.95	11.22	6.33
Net Income	-$47M	$146.18M	$3.50B	$382.15M
7 Day Performance	N/A	-0.28%	-0.90%	-1.40%
1 Month Performance	N/A	-1.88%	-4.44%	-3.47%
1 Year Performance	-86.79%	5.45%	7.02%	1.19%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	0.1104 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
VRAX Virax Biolabs Group	2.2256 of 5 stars	$2.00 -1.5%	$25.00 +1,150.0%	-89.0%	$1.59M	$12.42K	N/A	26	News Coverage Short Interest Decrease
BBLG Bone Biologics	0.6213 of 5 stars	$0.48 -1.3%	N/A	-82.7%	$1.32M	N/A	N/A	2	Gap Down
PFSA Profusa	0.2769 of 5 stars	$1.64 -1.2%	N/A	N/A	$1M	$100K	N/A	2	Short Interest Increase Gap Down
BTCY Biotricity	N/A	$0.05 flat	N/A	-92.2%	$964K	$12.06M	N/A	46

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. VRAX, BBLG, PFSA, BTCY, and GCTK

How does Venus Concept compare to Virax Biolabs Group?

Summary

How does Venus Concept compare to Bone Biologics?

Summary

How does Venus Concept compare to Profusa?

Summary

How does Venus Concept compare to Biotricity?

Summary

How does Venus Concept compare to GlucoTrack?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. VRAX, BBLG, PFSA, BTCY, and GCTK

How does Venus Concept compare to Virax Biolabs Group?

Which has more risk and volatility, VERO or VRAX?

Do analysts prefer VERO or VRAX?

Is VERO or VRAX more profitable?

Which has higher valuation & earnings, VERO or VRAX?

Does the media refer more to VERO or VRAX?

Do institutionals & insiders hold more shares of VERO or VRAX?

Summary

How does Venus Concept compare to Bone Biologics?

Is VERO or BBLG more profitable?

Do institutionals & insiders have more ownership in VERO or BBLG?

Which has more risk and volatility, VERO or BBLG?

Which has higher valuation & earnings, VERO or BBLG?

Does the media prefer VERO or BBLG?

Do analysts prefer VERO or BBLG?

Summary

How does Venus Concept compare to Profusa?

Which has more risk and volatility, VERO or PFSA?

Do institutionals and insiders hold more shares of VERO or PFSA?

Does the media refer more to VERO or PFSA?

Is VERO or PFSA more profitable?

Do analysts prefer VERO or PFSA?

Which has preferable earnings & valuation, VERO or PFSA?

Summary

How does Venus Concept compare to Biotricity?

Which has higher earnings & valuation, VERO or BTCY?

Do analysts prefer VERO or BTCY?

Does the media refer more to VERO or BTCY?

Which has more risk & volatility, VERO or BTCY?

Is VERO or BTCY more profitable?

Do institutionals & insiders hold more shares of VERO or BTCY?

Summary

How does Venus Concept compare to GlucoTrack?

Do institutionals & insiders hold more shares of GCTK or VERO?

Does the media refer more to GCTK or VERO?

Which has stronger valuation and earnings, GCTK or VERO?

Do analysts recommend GCTK or VERO?

Which has more risk and volatility, GCTK or VERO?

Is GCTK or VERO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools